Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 22, 2023 06:01 ET | Source: HOOKIPA Pharma Inc.

HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line setting—doubling historical ORR reported with...